Reset filter
Mots-clés
Pharmacotherapy ×
Afficher plus Mots-clés
Table des matières
  1. 1. Essai clinique
  2. 2. Routinedokumentation
  3. 3. Études de registres/cohortes
  4. 4. Assurance qualité
  5. 5. Standard de données
  6. 6. Questionnaire pour les patients
  7. 7. Spécialité médicale
Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

187 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

RANIBIZUMAB ADMINISTRATION FELLOW EYE (MONTH 25) CRFs Roche FVF4168G Macular Edema NCT00473330

- 01/07/2017 - 1 Formulaire, 2 Groupes Item, 10 Eléments de données, 1 Langue
Groupes Item: Patient administration, RANIBIZUMAB ADMINISTRATION FELLOW EYE (MONTH 25)
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

CONCOMITANT MEDICATIONS (DAY 0 - MONTH 12) CRFs Roche FVF4168G Macular Edema NCT00473330

- 11/06/2017 - 1 Formulaire, 3 Groupes Item, 11 Eléments de données, 1 Langue
Groupes Item: Patient administration, CONCOMITANT MEDICATIONS (DAY 0 - MONTH 12), Medication
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

CONCOMITANT MEDICATIONS (DAY 0 - MONTH 12) CRFs Roche FVF4170G Macular Edema NCT00473382

- 11/06/2017 - 1 Formulaire, 3 Groupes Item, 11 Eléments de données, 1 Langue
Groupes Item: Patient administration, CONCOMITANT MEDICATIONS (DAY 0 - MONTH 12), Medication
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4170g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

Eligibility Neurotoxicity NCT00301080

- 24/04/2017 - 1 Formulaire, 2 Groupes Item, 17 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
D-cycloserine in the Management of Chemotherapy-Induced Peripheral Neuropathic Pain; ODM derived from: https://clinicaltrials.gov/show/NCT00301080

Cumulative QTZ-EC-0004 ELEVATE NCT01713426

- 07/08/2016 - 1 Formulaire, 4 Groupes Item, 58 Eléments de données, 1 Langue
Groupes Item: Medication, Non-Medication Therapy, Adverse Event, Administration of Pregabalin
QUTENZA™ versus Pregabalin in Subjects with Peripheral Neuropathic Pain: an Open-label, Randomized, Multicenter, Non-inferiority Efficacy and Tolerability Study Medicine or Vaccine (generic name) capsaicin Sponsor Identification Number QTZ-EC-0004 Trial Registry Identification Number(#'s) NCT01713426 EudraCT Number: 2011-005872-41

Ciclosporin Psoriasis MIPSO EudraCT 2014-003022-40 DRKS00007147 - Ciclosporin Psoriasis MIPSO EudraCT 2014-003022-40

- 25/07/2016 - 1 Formulaire, 2 Groupes Item, 9 Eléments de données, 1 Langue
Groupes Item: Cyclosporine, Cyclosporine medication
MIPSO Vergleichende Untersuchung der bakteriellen Mikrobiota in der Haut sowie dem Darm von Psoriasis-Patienten vor und nach systemischer Behandlung mit Adalimumab bzw. Ustekinumab oder Ciclosporin (EudraCT 2014-003022-40) Principal Investigator: Prof. Dr. Dr. h.c. Thomas A. Luger

Adalimumab/Ustekinumab Psoriasis MIPSO EudraCT 2014-003022-40 DRKS00007147 - Adalimumab/Ustekinumab Psoriasis MIPSO EudraCT 2014-003022-40

- 23/07/2016 - 1 Formulaire, 2 Groupes Item, 7 Eléments de données, 1 Langue
Groupes Item: Adalimumab/Ustekinumab, Medication Adalimumab/Ustekinumab
MIPSO Vergleichende Untersuchung der bakteriellen Mikrobiota in der Haut sowie dem Darm von Psoriasis-Patienten vor und nach systemischer Behandlung mit Adalimumab bzw. Ustekinumab oder Ciclosporin (EudraCT 2014-003022-40) Principal Investigator: Prof. Dr. Dr. h.c. Thomas A. Luger

Baseline 1st cycle Trial Medication Multiple Sclerosis ALAIN01 NCT02419378

- 06/06/2016 - 1 Formulaire, 2 Groupes Item, 16 Eléments de données, 1 Langue
Groupes Item: Medication, Trial Medication RQG
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Baseline 1st cycle Trial Medication

Month 12 2nd cycle Trial Medication Multiple Sclerosis ALAIN01 NCT02419378

- 06/06/2016 - 1 Formulaire, 2 Groupes Item, 16 Eléments de données, 1 Langue
Groupes Item: Medication, Trial Medication RQG
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Month 12 2nd cycle Trial Medication

Discontinue Trial Medication Multiple Sclerosis ALAIN01 NCT02419378

- 28/05/2016 - 1 Formulaire, 1 Groupe Item, 6 Eléments de données, 1 Langue
Groupe Item: Discontinue Trial Medication
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany

Agent AML Pazopanib NCT01361334

- 11/02/2016 - 1 Formulaire, 2 Groupes Item, 14 Eléments de données, 2 Langues
Groupes Item: Medication Pazopanib, Medication Pazopanib
Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible (PAZOPANIB-AML) https://clinicaltrials.gov/ct2/show/NCT01361334 Principal Investigator: PD Dr. Torsten Kessler, University Hospital Muenster, Germany

Last Pazopanib AML Pazopanib NCT01361334

- 11/02/2016 - 1 Formulaire, 2 Groupes Item, 18 Eléments de données, 2 Langues
Groupes Item: Last Pazopanib, Pazopanib abgesetzt: RQG
Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible (PAZOPANIB-AML) https://clinicaltrials.gov/ct2/show/NCT01361334 Principal Investigator: PD Dr. Torsten Kessler, University Hospital Muenster, Germany

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial